Minimal Residual Disease Testing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

MRD testing has become a cornerstone of precision oncology, with clinical utility spanning leukemia, lymphoma, multiple myeloma, and increasingly solid tumors such as colorectal, breast, and lung cancers. The market encompasses a range of technologies, primarily next-generation sequencing (NGS) and polymerase chain reaction (PCR), as well as flow cytometry-based approaches. Growing integration of MRD testing into clinical trial endpoints and standard-of-care protocols has accelerated adoption among oncologists, hematologists, and pathologists worldwide.

• •Primary technologies include NGS (high-sensitivity, multi-target) and PCR (targeted, cost-effective for known mutations)
• •MRD testing is used for treatment monitoring, minimal residual disease detection in blood cancers, and emerging applications in solid tumors
• •Clinical and regulatory validation of MRD endpoints has expanded, supporting broader insurance reimbursement and hospital adoption

The rising global prevalence of cancer, combined with an aging population, is increasing the pool of patients eligible for MRD monitoring across multiple cancer types. Advances in genomic sequencing technologies have dramatically improved the sensitivity and accuracy of MRD assays, making them clinically actionable in settings where earlier methods lacked reliability. Additionally, pharmaceutical companies are increasingly incorporating MRD as a surrogate endpoint in oncology drug trials, creating significant demand from both clinical and research segments.

• •Growing cancer incidence rates worldwide, particularly in hematological malignancies, are expanding the patient base for MRD testing
• •Technological improvements in NGS and PCR have lowered detection limits to 10^-5 or 10^-6 sensitivity, enabling earlier relapse prediction
• •Expanding use of MRD as a surrogate endpoint in drug development by biopharmaceutical companies is driving laboratory and commercial demand

The market is segmented by technology (NGS, PCR, and other methods), cancer type (hematological malignancies and solid tumors), and end-use (hospitals, diagnostic laboratories, and research institutions). Hematological malignancies currently dominate MRD testing due to the well-established clinical utility in diseases such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. Geographically, North America leads the market, supported by advanced healthcare infrastructure, favorable reimbursement policies, and strong research activity, while Europe and the Asia-Pacific region are experiencing rapid growth driven by increasing healthcare investment and expanding access to precision diagnostics.

• •NGS is the fastest-growing technology segment, driven by its multiplexing capability and decreasing per-sample costs
• •Hospitals represent the largest end-use segment, though independent diagnostic laboratories are gaining share due to specialization and scale
• •Asia-Pacific is an emerging high-growth region, fueled by rising cancer burden, improving diagnostic capacity, and growing adoption of advanced genomic medicine

What are the recent trends and outlook?

Expansion of MRD testing into solid tumors represents the next major growth frontier, with ongoing clinical studies evaluating MRD as a predictor of recurrence in cancers where blood-based minimal residual disease monitoring has historically been more challenging. Multiplexed and liquid-biopsy-based MRD assays capable of simultaneously detecting multiple cancer types from a single blood draw are gaining momentum. Regulatory bodies are also evolving frameworks for MRD-based companion diagnostics and surrogate endpoints, which could unlock new commercial pathways. Over the coming decade, the convergence of AI-driven genomic analysis, broader reimbursement coverage, and continued clinical validation is expected to sustain the market's double-digit growth trajectory toward the projected $5.19 billion by 2035.

• •Liquid biopsy and circulating tumor DNA (ctDNA)-based MRD assays are expanding applications beyond blood cancers into solid tumors
• •Artificial intelligence and machine learning are being integrated to improve MRD signal interpretation from complex NGS datasets
• •Regulatory recognition of MRD as a validated clinical endpoint is expected to accelerate, supporting wider insurance coverage and market expansion